<unk>  was first described in 1906 by G. Joachim.<unk>  may be classified into two categories based on prognosis. Based on the duration of symptoms,<unk>  may be classified into either acute or chronic. Genes involved in the pathogenesis of<unk>  include KIT D816V and non-KIT D816V. There are no characteristic findings of<unk>  on gross pathology. On microscopic histopathological analysis, multifocal sheets and clusters of<unk>  cells in bone marrow sections are findings of<unk> . Common causes of<unk>  include genetic mutations. Common genetic mutations involved in the development of<unk>  can be found here.<unk>  must be differentiated from other diseases such as systemic<unk> ocytosis, myelomastocytic leukemia, hairy cell leukemia, reactive<unk>  cell hyperplasia, and peripheral T-cell leukemia. The incidence of<unk>  increases with age; the median age at diagnosis is 52 years.<unk>  commonly affects individuals between 5 to 76 years of age. Females are more commonly affected with<unk>  than males. The female to male ratio is 1.5 to 1.<unk>  usually affects individuals of the Caucasian race. Risk factor for<unk>  is systemic<unk> ocytosis, a premalignant condition. Factors involved in malignant transformation of systemic<unk> ocytosis into<unk>  include advanced age, history of weight loss, anemia, thrombocytopenia, hypoalbuminemia, and an excess of bone marrow blasts. According to the United States Preventive Services Task Force, there is insufficient evidence to recommend routine screening for<unk> . If left untreated,patients with<unk>  may progress to develop weight loss, ascites, and bone abnormalities. Common complications of<unk>  include hepatosplenomegaly, lymphadenopathy, and osteoporosis. Prognosis is generally poor, and the median survival time is less than six months. Symptoms of<unk>  include fever, weight loss, weakness, flushes, and pruritis. Common physical examination findings of<unk>  include hepatosplenomegaly, lymphadenopathy, bone abnormalities, and ascites.Laboratory findings consistent with the diagnosis of<unk>  include abnormal complete blood count, biochemistry, and immunohistochemistry. The mainstay of therapy for symptomatic<unk>  patients is immunochemotherapy.
Mast cell leukemia
Leukemoid reaction
Hemophagocytic lymphohistiocytosis
Acute basophilic leukemia
Prolymphocytic leukemia
T-cell leukemia
Monocytic leukemia
Adult T-cell leukemia